• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

respiratory syncytial virus

Pediatrician pretending to listen to heartbeat of teddy bear with baby and mother watching
Research

Blood from pediatricians yields new antiviral antibodies

Researchers now hope to turn an antibody cocktail into a new treatment or preventative for respiratory syncytial virus and human metapneumovirus.
Darren Incorvaia Feb 18, 2026 2:15pm
Union Square in San Francisco during JPM 2026

JPM26: Sanofi looks ahead to lingering US policy hurdles

Jan 14, 2026 2:28pm
Rendered image of a respiratory syncytial virus

Sanofi drops toddler RSV vaccine after ph. 3 heads for failure

Oct 24, 2025 7:00am
RSV

Enanta sees RSV drug fail phase 2b but finds positives

Sep 29, 2025 8:05am
Gilead

Gilead blames low infection rates for ending 2 RSV trials

Jun 27, 2025 4:09am
RSV virus

Shionogi's RSV antiviral reduces viral load in ph. 2 adult trial

Jan 30, 2025 5:32am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings